Physician
Endocrinology
Dr. Michael A. Bolognese, MD
|
|
Give Review
Michael A. Bolognese works in the field of Endocrinology. He researched medicine at Drexel University College of Medicine. He received 1 awards: "Fellow (FACE)". Michael Bolognese is also a published doctor. He has 41 publication published. The most recent publication is: References on sodium-retaining potency of corticosteroids. Michael A. Bolognese accepts Medicare.
Publications
- A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women with Osteoporosis Receiving Teriparatide or Zol...
- A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
- Effects of up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension.
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia.
- Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who rem...
- Anti-PCSK9 Monotherapy for Hypercholesterolemia - The MENDEL-2 Randomized, Controlled Phase 3 Clinical Trial of Evolocumab.
- The clinical diagnosis of Osteoporosis: a position statement from the National Bone Health Alliance Working Group.
- Romosozumab in Postmenopausal Women with Low Bone Mineral Density.
- Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with Osteoporosis treated with denosumab.
- Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial.
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.
- Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.
- SERMs and SERMs with estrogen for postmenopausal Osteoporosis.
- Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women.
- Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study.
- Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
- Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
- Effects of atorvastatin on bone in postmenopausal women with dysLipidemia: a double-blind, placebo-controlled, dose-ranging trial.
- Ibandronate: the evolution of a once-a-month oral therapy for postmenopausal Osteoporosis.
- Monthly oral ibandronate therapy in postmenopausal Osteoporosis: 1-year results from the MOBILE study.
- Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
- Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal Osteoporosis.
- Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteopo...
- Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.
- Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
- Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a rando...
- Denosumab in postmenopausal women with low bone mineral density.
- A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
- The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal Osteoporosis.
- Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
- Cinacalcet HCl reduces Hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.
- Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Iba...
- The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with Osteopenia: results of a 1-year phase 2 double-blind, placebo-controlled, r...
- Intravenous ibandronate injections in postmenopausal women with Osteoporosis: one-year results from the dosing intravenous administration study.
- Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
- Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass.
- References on sodium-retaining potency of corticosteroids.
- Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
Schools
Drexel University College of Medicine
Hltheast Tch Hp Allentown Hp
Loma Linda University Med Center
Long Beach Mem Med Center
Conditions Treated
- Calcium Metabolism Disorders
- Diabetes Type 2
- Hypercalcemia
- HyperLipidemia
- View All
Doctors Specialties
- Diabetes Medicine
- Endocrinology
Accepted Insurances
Awards
- Fellow (FACE)
Education
-
Loma Linda University -
Drexel University College of Medicine
Drug Facts
| NPI NUMBER | 1184713190 | |
| NPPES Provider LastName | BOLOGNESE | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 208171183 | |
| NPPES Provider State | MD | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 228.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184713190 |
| Last Name Of The Provider | BOLOGNESE |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Joshua J. Zimmerberg |
|
|
Dr. Becky T. Muldoon, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Babette C. Glister, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick W. Clyde, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carolyn A. Bondy, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Joanna K. Zawadzki, MD |
|
|
Dr. Lynnette Nieman, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Irene A. Feldman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Safa M. Rifka, MD
This Doctor is OpenDoctor Recommended.
|